Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer

Charles E. Cox, John M. Cox, Laura B. White, Nicholas G. Stowell, John D. Clark, Nathon Allred, Michael Meyers, Elisabeth Dupont, Ben Furman, Susan Minton

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Treatment of locally advanced breast cancer with neoadjuvant chemotherapy assesses an in vivo tumor response while increasing breast conservation. Axillary clearance of nodal disease after treatment defines prognostic stratification. Our study objective was to show that sentinel node staging before treatment can optimize posttreatment prognostic stratification in clinically NO patients. Methods: Eighty-nine patients with locally advanced breast cancer were treated with neoadjuvant chemotherapy. Of these, 42 (47%) clinically palpable or image-detected nodes (cN+) were histologically confirmed before treatment (group 1), and 47 (53%) patients without palpable lymph nodes (cN0) had a sentinel lymph node (SLN) biopsy before treatment (group 2). Survival analysis was conducted with the Kaplan-Meier method. Results: In groups 1 and 2, 82 (92%) of 89 patients had node-positive disease before treatment. Seven (8%) of 89 had negative SLNs and no completion axillary lymph node dissection, 24 (27%) patients had a complete pathologic axillary response (pCRAX; 11 [26%] of 42 in group 1 and 13 [33%] of 40 in group 2), and 58 (65%) of 89 had residual disease in the axilla. Breast-conserving therapy was applied to 27 (30%) of 89 patients. The seven SLN-negative patients had no axillary recurrence at 25 months, and pCRAX patients had a significantly higher overall survival than patients with residual disease. Conclusions: This study validates the prognostic stratification of patients with a complete pathologic axillary response to neoadjuvant chemotherapy. The addition of SLN biopsy to cN0 patients before treatment increased accurate nodal staging by 53%, eliminated completion axillary lymph node dissection in 15%, and demonstrated an improved prognosis in 28% of pCRAX patients. SLN biopsy before treatment provides accurate staging of cN0 patients; allows acquisition of standard treatment markers, prognostic biomarkers, and microarray analysis; and affords prognostic stratification after treatment.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalAnnals of Surgical Oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

Breast Neoplasms
Biopsy
Drug Therapy
Sentinel Lymph Node Biopsy
Therapeutics
Lymph Node Excision
cyhalothrin
Breast
Axilla
Microarray Analysis
Survival Analysis
Biomarkers
Lymph Nodes
Recurrence
Survival

Keywords

  • Axillary staging
  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Sentinel lymph node mapping

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. / Cox, Charles E.; Cox, John M.; White, Laura B.; Stowell, Nicholas G.; Clark, John D.; Allred, Nathon; Meyers, Michael; Dupont, Elisabeth; Furman, Ben; Minton, Susan.

In: Annals of Surgical Oncology, Vol. 13, No. 4, 01.04.2006, p. 483-490.

Research output: Contribution to journalArticle

Cox, Charles E. ; Cox, John M. ; White, Laura B. ; Stowell, Nicholas G. ; Clark, John D. ; Allred, Nathon ; Meyers, Michael ; Dupont, Elisabeth ; Furman, Ben ; Minton, Susan. / Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. In: Annals of Surgical Oncology. 2006 ; Vol. 13, No. 4. pp. 483-490.
@article{a6c6211459e94597bc88655b8441d56b,
title = "Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer",
abstract = "Background: Treatment of locally advanced breast cancer with neoadjuvant chemotherapy assesses an in vivo tumor response while increasing breast conservation. Axillary clearance of nodal disease after treatment defines prognostic stratification. Our study objective was to show that sentinel node staging before treatment can optimize posttreatment prognostic stratification in clinically NO patients. Methods: Eighty-nine patients with locally advanced breast cancer were treated with neoadjuvant chemotherapy. Of these, 42 (47{\%}) clinically palpable or image-detected nodes (cN+) were histologically confirmed before treatment (group 1), and 47 (53{\%}) patients without palpable lymph nodes (cN0) had a sentinel lymph node (SLN) biopsy before treatment (group 2). Survival analysis was conducted with the Kaplan-Meier method. Results: In groups 1 and 2, 82 (92{\%}) of 89 patients had node-positive disease before treatment. Seven (8{\%}) of 89 had negative SLNs and no completion axillary lymph node dissection, 24 (27{\%}) patients had a complete pathologic axillary response (pCRAX; 11 [26{\%}] of 42 in group 1 and 13 [33{\%}] of 40 in group 2), and 58 (65{\%}) of 89 had residual disease in the axilla. Breast-conserving therapy was applied to 27 (30{\%}) of 89 patients. The seven SLN-negative patients had no axillary recurrence at 25 months, and pCRAX patients had a significantly higher overall survival than patients with residual disease. Conclusions: This study validates the prognostic stratification of patients with a complete pathologic axillary response to neoadjuvant chemotherapy. The addition of SLN biopsy to cN0 patients before treatment increased accurate nodal staging by 53{\%}, eliminated completion axillary lymph node dissection in 15{\%}, and demonstrated an improved prognosis in 28{\%} of pCRAX patients. SLN biopsy before treatment provides accurate staging of cN0 patients; allows acquisition of standard treatment markers, prognostic biomarkers, and microarray analysis; and affords prognostic stratification after treatment.",
keywords = "Axillary staging, Locally advanced breast cancer, Neoadjuvant chemotherapy, Sentinel lymph node mapping",
author = "Cox, {Charles E.} and Cox, {John M.} and White, {Laura B.} and Stowell, {Nicholas G.} and Clark, {John D.} and Nathon Allred and Michael Meyers and Elisabeth Dupont and Ben Furman and Susan Minton",
year = "2006",
month = "4",
day = "1",
doi = "10.1245/ASO.2006.03.592",
language = "English (US)",
volume = "13",
pages = "483--490",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer

AU - Cox, Charles E.

AU - Cox, John M.

AU - White, Laura B.

AU - Stowell, Nicholas G.

AU - Clark, John D.

AU - Allred, Nathon

AU - Meyers, Michael

AU - Dupont, Elisabeth

AU - Furman, Ben

AU - Minton, Susan

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Treatment of locally advanced breast cancer with neoadjuvant chemotherapy assesses an in vivo tumor response while increasing breast conservation. Axillary clearance of nodal disease after treatment defines prognostic stratification. Our study objective was to show that sentinel node staging before treatment can optimize posttreatment prognostic stratification in clinically NO patients. Methods: Eighty-nine patients with locally advanced breast cancer were treated with neoadjuvant chemotherapy. Of these, 42 (47%) clinically palpable or image-detected nodes (cN+) were histologically confirmed before treatment (group 1), and 47 (53%) patients without palpable lymph nodes (cN0) had a sentinel lymph node (SLN) biopsy before treatment (group 2). Survival analysis was conducted with the Kaplan-Meier method. Results: In groups 1 and 2, 82 (92%) of 89 patients had node-positive disease before treatment. Seven (8%) of 89 had negative SLNs and no completion axillary lymph node dissection, 24 (27%) patients had a complete pathologic axillary response (pCRAX; 11 [26%] of 42 in group 1 and 13 [33%] of 40 in group 2), and 58 (65%) of 89 had residual disease in the axilla. Breast-conserving therapy was applied to 27 (30%) of 89 patients. The seven SLN-negative patients had no axillary recurrence at 25 months, and pCRAX patients had a significantly higher overall survival than patients with residual disease. Conclusions: This study validates the prognostic stratification of patients with a complete pathologic axillary response to neoadjuvant chemotherapy. The addition of SLN biopsy to cN0 patients before treatment increased accurate nodal staging by 53%, eliminated completion axillary lymph node dissection in 15%, and demonstrated an improved prognosis in 28% of pCRAX patients. SLN biopsy before treatment provides accurate staging of cN0 patients; allows acquisition of standard treatment markers, prognostic biomarkers, and microarray analysis; and affords prognostic stratification after treatment.

AB - Background: Treatment of locally advanced breast cancer with neoadjuvant chemotherapy assesses an in vivo tumor response while increasing breast conservation. Axillary clearance of nodal disease after treatment defines prognostic stratification. Our study objective was to show that sentinel node staging before treatment can optimize posttreatment prognostic stratification in clinically NO patients. Methods: Eighty-nine patients with locally advanced breast cancer were treated with neoadjuvant chemotherapy. Of these, 42 (47%) clinically palpable or image-detected nodes (cN+) were histologically confirmed before treatment (group 1), and 47 (53%) patients without palpable lymph nodes (cN0) had a sentinel lymph node (SLN) biopsy before treatment (group 2). Survival analysis was conducted with the Kaplan-Meier method. Results: In groups 1 and 2, 82 (92%) of 89 patients had node-positive disease before treatment. Seven (8%) of 89 had negative SLNs and no completion axillary lymph node dissection, 24 (27%) patients had a complete pathologic axillary response (pCRAX; 11 [26%] of 42 in group 1 and 13 [33%] of 40 in group 2), and 58 (65%) of 89 had residual disease in the axilla. Breast-conserving therapy was applied to 27 (30%) of 89 patients. The seven SLN-negative patients had no axillary recurrence at 25 months, and pCRAX patients had a significantly higher overall survival than patients with residual disease. Conclusions: This study validates the prognostic stratification of patients with a complete pathologic axillary response to neoadjuvant chemotherapy. The addition of SLN biopsy to cN0 patients before treatment increased accurate nodal staging by 53%, eliminated completion axillary lymph node dissection in 15%, and demonstrated an improved prognosis in 28% of pCRAX patients. SLN biopsy before treatment provides accurate staging of cN0 patients; allows acquisition of standard treatment markers, prognostic biomarkers, and microarray analysis; and affords prognostic stratification after treatment.

KW - Axillary staging

KW - Locally advanced breast cancer

KW - Neoadjuvant chemotherapy

KW - Sentinel lymph node mapping

UR - http://www.scopus.com/inward/record.url?scp=33644986354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644986354&partnerID=8YFLogxK

U2 - 10.1245/ASO.2006.03.592

DO - 10.1245/ASO.2006.03.592

M3 - Article

C2 - 16523361

AN - SCOPUS:33644986354

VL - 13

SP - 483

EP - 490

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -